Dual GLP-1/GIP Agonists for Weight Loss: Every Trial Number
GLP-1 medicines approved for type 2 diabetes are Ozempic, Rybelsus, Mounjaro, Trulicity, Victoza and Byetta. Ozempic, Rybelsus, Mounjaro, Trulicity and Victoza also carry an approval to lower heart attack and stroke risk. Metformin, DPP-4 pills, SGLT2 pills, sulfonylureas and insulin are the other main groups.
- GLP-1s for type 2 diabetes
- 6
- With a heart-risk approval
- Ozempic, Rybelsus, Mounjaro, Trulicity and Victoza
Weight loss and half-life at a glance
Half-life in days: how long your body takes to clear half a dose. Each FDA label gives this figure in 12.3.
Percentage of body weight. Trials, doses and lengths differ. On its page, compare each result with the placebo from the same trial.
GLP-1 diabetes medicines compared
| Medicine | Ingredient | How it is taken | Approved for | Most common side effect | Self-pay from | List price |
|---|---|---|---|---|---|---|
 Ozempic | semaglutide | Weekly injection | Type 2 diabetes and heart risk, along with kidney disease affecting people who have type 2 diabetes | Nausea 20.3% vs 6.1% on placebo | $199 per month | $1,027.51 per pen |
 Rybelsus | semaglutide | Daily tablet | Type 2 diabetes and heart risk | Nausea 20% vs 6% on placebo | Not listed | $1,027.51 per 30 tablets |
 Mounjaro | tirzepatide | Weekly injection | Type 2 diabetes and heart risk | Nausea 18% vs 4% on placebo | Not listed | $1,112.16 per fill |
 Trulicity | dulaglutide | Weekly injection | Type 2 diabetes and heart risk | Nausea 21.1% vs 5.3% on placebo | Not listed | $1,006.93 per fill |
 Victoza | liraglutide | Daily injection | Type 2 diabetes and heart risk | Nausea 20% vs 5% on placebo | Not listed | $543.51 per 2 pens |
| Byetta | exenatide | Twice-daily injection | Type 2 diabetes | Nausea 44% vs 18% on placebo | Not listed | Not listed |
Low blood sugar when combining treatments
Taking insulin or a sulfonylurea with it increases the chance of low blood sugar, and those doses may need lowering.
Sources: FDA label (DailyMed).